Iovance Biotherapeutics, Inc.
IOVA
$2.30
-$0.01-0.43%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
6/29/2025
-
MarketBeat
11/7/2025
-
MarketBeat
11/7/2025
-
MarketBeat
11/7/2025
-
MarketBeat
11/7/2025
-
Zacks Investment Research
11/7/2025
-
MarketBeat
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
11/7/2025
-
Fool.com Headlines
11/6/2025
-
GuruFocus
11/6/2025
-
GuruFocus
11/6/2025
-
GuruFocus
11/6/2025
-
GuruFocus
11/6/2025
-
TipRanks Financial Blog
11/6/2025
-
Simply Wall St
11/6/2025
-
Zacks Investment Research
11/6/2025
-
GuruFocus
11/6/2025
-
GuruFocus
11/6/2025
-
The Fly
11/6/2025
-
GuruFocus
11/6/2025
-
Globe Newswire
11/5/2025
-
Zacks Investment Research
11/5/2025
-
Benzinga
11/4/2025
-
Zacks Investment Research
11/4/2025
-
MarketBeat
11/4/2025
-
MarketBeat
11/4/2025
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
650 260 7120
Address
825 Industrial Road
San Carlos, CA 94070
San Carlos, CA 94070
Country
Year Founded
Business Description
Sector
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of...
more